Mithramycin selectively attenuates DNA-damage-induced neuronal cell death

Oleg Makarevich1, Boris Sabirzhanov1, Taryn G Aubrecht1

  • 1Department of Anesthesiology and Shock, Trauma and Anesthesiology Research (STAR) Center, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.

Cell Death & Disease
|July 29, 2020
PubMed

Insights

Mithramycin protects neurons from chemotherapy-induced death by inhibiting Sp1 binding to gene promoters, thus blocking p53-mediated apoptosis. This drug shows potential for treating neurological disorders involving DNA damage and neuronal loss.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Cell Death Research

Background:

  • DNA damage is a key factor in neuronal loss and cognitive decline in conditions like TBI and chemotherapy side effects.
  • Specificity protein 1 (Sp1) plays a role in regulating gene transcription involved in cell death pathways.

Purpose of the Study:

  • To investigate the neuroprotective mechanisms of Mithramycin in DNA damage-induced neuronal cell death.
  • To explore the role of Sp1 in p53-mediated apoptosis in neurons.

Main Methods:

  • Utilized primary rat neurons in vitro and a mouse model of traumatic brain injury (TBI).
  • Exposed neurons to DNA-damage-inducing chemotherapy drugs.
  • Administered Mithramycin to assess its neuroprotective effects.
  • Performed chromatin immunoprecipitation to analyze Sp1 and p53 binding to gene promoters.

Main Results:

  • Mithramycin demonstrated significant neuroprotection against DNA-damage-dependent neuronal death by inhibiting apoptosis cascades downstream of ATM and p53.
  • Mithramycin reduced the upregulation of pro-apoptotic BH3-only proteins and mitochondrial dysfunction.
  • Chromatin immunoprecipitation revealed Mithramycin attenuates Sp1 binding to pro-apoptotic gene promoters, suggesting interference with p53 transactivation.

Conclusions:

  • Sp1 is essential for p53-mediated transactivation of neuronal pro-apoptotic molecules.
  • Mithramycin may serve as a therapeutic agent to attenuate neuronal cell death in conditions characterized by DNA damage and p53-dependent intrinsic apoptosis.